Investor science event: Getting ahead of respiratory syncytial virus in older adults

After presenting the positive AReSVi-006 pivotal phase III results for our RSV (respiratory syncytial virus) older adults vaccine candidate at IDWeek 2022, GSK management hosted an investor science event on 21 October 2022.